Combination of Azelastine Nasal Spray and Fexofenadine for Allergic Rhinitis

Pharmacologic Compatibility

Intranasal azelastine and oral fexofenadine have no known pharmacological contraindications or drug‑interaction concerns because they act via complementary mechanisms—azelastine provides rapid topical H1‑receptor blockade within ≈ 15 minutes, while fexofenadine offers systemic H1‑receptor antagonism. 1

In patients with seasonal allergic rhinitis who remain symptomatic on fexofenadine alone, azelastine nasal spray monotherapy achieves symptom improvement (Total Nasal Symptom Score) comparable to the azelastine + fexofenadine combination, with similar benefits for runny nose, sneezing, itchy nose, and nasal congestion. 1
Azelastine nasal spray alone effectively treats all four cardinal nasal symptoms—including nasal congestion—whereas oral antihistamines such as fexofenadine have limited impact on congestion. [2][3]
Adding an intranasal corticosteroid (e.g., fluticasone propionate) to azelastine yields approximately a 40 % greater reduction in overall symptom scores than either azelastine alone or azelastine combined with an oral antihistamine, making the steroid‑plus‑azelastine regimen the most efficacious option for refractory cases. 3

Fexofenadine is consistently non‑sedating, even at doses exceeding the standard recommendation, and is therefore the safest oral antihistamine when avoidance of drowsiness is essential. 2
Azelastine nasal spray is associated with low somnolence rates (0.4 %–3 %), comparable to placebo in recent studies; older reports noted higher rates (up to 11.5 %). The theoretical additive sedation risk when both agents are used together is minimal and rarely clinically significant. 3

The most common adverse effect of azelastine nasal spray is a bitter taste, reported in roughly 8 %–20 % of users. Patients should be counseled about this possibility. 1

Fexofenadine: 60 mg taken twice daily or 180 mg once daily for adults. 4
Azelastine nasal spray: Two sprays per nostril twice daily (0.1 % or 0.15 % formulation) for individuals aged ≥ 6 years. 3
Continuous daily administration of both agents provides superior control of seasonal or perennial allergic rhinitis compared with as‑needed use; however, azelastine’s rapid onset permits episodic dosing when symptoms are truly intermittent. [2][1]